Good and sustained response to pembrolizumab and pazopanib in advanced undifferentiated pleomorphic sarcoma: a case report.

Arora, Shalabh; Rastogi, Sameer; Shamim, Shamim Ahmed; Barwad, Adarsh; Sethi, Maansi

Arora, Shalabh; Rastogi, Sameer; Shamim, Shamim Ahmed; Barwad, Adarsh; Sethi, Maansi.

Afiliación

Arora S; Department of Medical Oncology, Dr B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Rastogi S; Department of Medical Oncology, Dr B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Shamim SA; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Barwad A; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Sethi M; Department of Ophthalmology, Lady Hardinge Medical College, New Delhi, India.

Clin Sarcoma Res ; 10: 10, 2020.

Article en En | MEDLINE | ID: mdl-32670543

Palabras clave

Immunotherapy; Pazopanib; Pembrolizumab; Undifferentiated pleomorphic sarcoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Clin Sarcoma Res Año: 2020 Tipo del documento: Article País de afiliación: India